Malaria antibody protects Mali infants but lowers R21 response in study

Researchers found L9LS was 78% effective against parasite infection in Malian infants, but those given it before the R21 vaccine had 20% to 30% lower vaccine-induced antibody levels.
In this article
A malaria antibody protected infants in Mali against parasite infection but reduced their antibody response to a subsequent vaccine, researchers found. An abstract presented at the American Society of Tropical Medicine and Hygiene meeting said L9LS was 78% effective against infection compared with a placebo over a six-month transmission season; vaccine-induced antibody levels fell 20% to 30% in infants given L9LS before R21.
Researchers had hoped an antibody injection could protect babies before their first malaria vaccine dose. R21 and another vaccine, RTS,S, require multiple doses, starting at 5 months of age. It is not yet clear what the lower antibody levels mean for R21's protection against clinical malaria.
How the study tested the combination
L9LS is a monoclonal antibody, a laboratory-made antibody designed to bind to a particular target. The study gave infants aged 1 to 12 months either L9LS or a placebo, followed by R21 doses, STAT reported.
The trial listing planned to enroll 180 infants and randomly assign equal numbers, grouped by age, to an L9LS injection or a saline placebo. Neither participants nor researchers would know which injection an infant received. The plan called for 3 R21 doses, 4 weeks apart, beginning approximately 5 months after the injection. The trial was designed to assess safety, how L9LS moves through the body, vaccine antibody responses, anti-drug antibodies and parasite infection.
Both L9LS and R21 target a protein on the malaria parasite called the circumsporozoite protein. Researchers believe L9LS also bound to the vaccine, interfering with the immune response R21 was meant to trigger.
Analysis
Other groups considered for trials
Researchers plan to focus on groups other than infants in pivotal studies that could support approval of L9LS, which they hope to start in 2028. Robert Seder of the National Institute of Allergy and Infectious Diseases, whose laboratory helped develop L9LS, said researchers could pursue other uses first and revisit the infant question later.
Experts identified pregnant people and children recently discharged from hospital after malaria as possible groups for future studies. Another infection can be especially dangerous for children recovering from malaria-related anemia. A single injection could protect them for months, rather than requiring the monthly preventive drugs currently used after discharge.
André-Marie Tchouatieu of Medicines for Malaria Venture, who was not involved in the study, said L9LS and newer antibodies could still help reduce malaria’s burden. Antibodies are comparatively costly, although efforts are underway to lower the price per dose.
Follow AveNews
Earlier in Science
Physics, Maths & DiscoveriesArchaeologists found about 3 Maya sculptures at El Mirador in 2026
The new stucco finds in Guatemala need restoration. They add to a collection of earlier heads that researchers say offers a rare view of Maya artistry.
2 min
SpaceRelativity Space fires Terran R stage for over 400 seconds
The first-flight second stage completed its ground test on the first attempt, and Relativity has finished structural qualification testing of the rocket’s primary structures.
3 min
EarthEthiopia’s Fentale released at least 38 kilotonnes of methane in 2024–25
The volcano did not erupt. A University of Bristol-led study proposes that a sheet of underground magma broke a seal and freed methane trapped beneath it.
2 min
